Table 1.

Risk factors associated with response (sustained virologic response 12) to first-generation direct acting antivirals in naive patients

	SVR12 rates (%)
	Boceprevir			Telaprevir
Predictive variables	PR48	BOCRGT	BOCPR48	PR48	T12PR48
Naïve	40	67	66	44	75
Mild-moderate fibrosis	38	67	67	47	118.5
Advanced fibrosis	38	41	52	33	62
Black race	23	42	53	25	62
HCVRNA viral load < 800.000 IU/mL	64	76	85	36	74
IL28B C/C	78	82	80	64	90
Il28B C/T	28	65	71	23	71
IL28B T/T	27	55	59	25	73
HCV genotype 1a	35	59	63	41	71
HCV genotype 1b	40	66	70	4	79
BMI < 25	47	58	67	44	83
BMI ≥ 30	33	48	66	41	71
Relapse	22	9	9	28	9

Data obtained, analyzed and adapted from Ref. [8,9,44]. PR48: Standard therapy with pegylated interferon plus ribavirin for 48 wk; BOCRGT: Boceprevir with therapy possibly shortened by response guided therapy; BOCPR48: Boceprevir with treatment fixed time for 48 wk; T12PR48: Telaprevir by 12 wk and standard therapy for 48 wk; IL28B: Interleukin-28B; BMI: Body mass index; HCV: Hepatitis C virus; SVR: Sustained virologic response.